Jing Me Liu

US Patent:

20100323393, Dec 23, 2010

Filed:

Jun 22, 2010

Appl. No.:

12/820933

Inventors:

Xiuli An - Bayside NY, US
Mohandas Narla - New York NY, US
Jing Liu - Woodside NY, US
Susanne Heck - Bronx NY, US

International Classification:

C12Q 1/06
C12N 5/078
C12Q 1/02
C12Q 1/04

US Classification:

435 39, 435325, 435 29, 435 34

Abstract:

Disclosed herein are methods for the isolation, identification, and quantification of red blood cells and red blood cell precursors at different developmental stages. Also disclosed are methods for monitoring ex vivo proliferation and differentiation of red blood cells and red blood cell progenitors.

US Patent:

20120295285, Nov 22, 2012

Filed:

Jul 13, 2012

Appl. No.:

13/548761

Inventors:

Xiuli An - Bayside NY, US
Mohandas Narla - New York NY, US
Jing Liu - Woodside NY, US
Susanne Heck - Bronx NY, US

Assignee:

NEW YORK BLOOD CENTER, INC. - New York NY

International Classification:

C12Q 1/04
G01N 21/64
G01N 33/566
C12Q 1/06

US Classification:

435 725, 435 34, 435 39

Abstract:

Disclosed herein are methods for the isolation, identification, and quantification of red blood cells and red blood cell precursors at different developmental stages. Also disclosed are methods for monitoring ex vivo proliferation and differentiation of red blood cells and red blood cell progenitors.

US Patent:

20130017250, Jan 17, 2013

Filed:

Jul 16, 2012

Appl. No.:

13/550567

Inventors:

Henry Ginsberg - Dobbs Ferry NY, US
Jing Liu - New York NY, US

Assignee:

The Trustees of Columbia University in the City of New York - New York City NY

International Classification:

A61K 38/44
G01N 21/76
A61P 3/10
C07H 21/04
A61K 9/127
A61P 9/00
G01N 21/17
G01N 21/64

US Classification:

424450, 435 29, 435 8, 424 944, 536 241

Abstract:

It was discovered that insulin binding to insulin receptors signals the upregulation of expression of the liver enzyme deiodinase 1 (Dio1), which in turn activates the ApoA-1 promoter, thereby thereby increasing ApoA-1 expression (primarily in the liver), that in turn raises the levels of plasma ApoA-1, the major and necessary protein in HDLC. Certain embodiments of the invention are directed to methods for increasing circulating HDLC levels in an animal by administering therapeutically effective amounts of Dio1, or by increasing the level of Dio1 through gene therapy.

US Patent:

20130158258, Jun 20, 2013

Filed:

Feb 12, 2013

Appl. No.:

13/765639

Inventors:

Janssen Pharmaceutica NV - New Brunswick NJ, US
Frank CHAVEZ - San Diego CA, US
James P. EDWARDS - San Diego CA, US
Annie E. FITZGERALD - San Diego CA, US
Jing LIU - San Diego CA, US
Neelakandha S. MANI - San Diego CA, US
Michele C. RIZZOLIO - San Diego CA, US
Brad M. SAVALL - San Diego CA, US
Deborah M. SMITH - San Diego CA, US
Jennifer D. VENABLE - Solana Beach CA, US
Jianmei WEI - San Diego CA, US
Danielle K. WIENER - La Jolla CA, US
Ronald L. WOLIN - San Diego CA, US

Assignee:

Janssen Pharmaceutica NV - New Brunswick NJ

International Classification:

C07D 239/48
C07D 471/04
C07D 405/14
C07D 409/14
C07D 487/10
C07D 403/04

US Classification:

540575, 544230, 544295, 544323

Abstract:

2-Aminopyrimidine compounds are described, which are useful as Hreceptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by Hreceptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

US Patent:

20130158259, Jun 20, 2013

Filed:

Feb 13, 2013

Appl. No.:

13/766375

Inventors:

JANSSEN PHARMACEUTICA NV - New Brunswick NJ, US
Frank CHAVEZ - San Diego CA, US
James P. EDWARDS - San Diego CA, US
Annie E. FITZGERALD - San Diego CA, US
Jing LIU - San Diego CA, US
NEELAKANDHA S. MANI - San Diego CA, US
Michele C. RIZZOLIO - San Diego CA, US
Brad M. SAVALL - San Diego CA, US
Deborah M. SMITH - San Diego CA, US
Jennifer D. VENABLE - Solana Beach CA, US
Jianmei WEI - San Diego CA, US
Danielle K. WIENER - La Jolla CA, US
Ronald L. WOLIN - San Diego CA, US

Assignee:

JANSSEN PHARMACEUTICA NV - New Brunswick NJ

International Classification:

C07D 498/04
C07D 401/04
C07D 403/04
C07D 487/04
C07D 487/10
C07D 487/08
C07D 405/04
C07D 405/14
C07D 239/95
C07D 239/70
C07D 239/48
C07D 471/04

US Classification:

540575, 544295, 544323, 544253, 544230, 544105

Abstract:

2-Aminopyrimidine compounds are described, which are useful as Hreceptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by Hreceptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

US Patent:

20220348580, Nov 3, 2022

Filed:

Jun 21, 2019

Appl. No.:

17/254345

Inventors:

- New York NY, US
- Chapel Hill NC, US
Jing Liu - New York NY, US
Xufen Yu - New York NY, US
Dongxu Li - Chapel Hill NC, US

International Classification:

C07D 487/04
C07D 401/14
C07D 417/14

Abstract:

Disclosed herein are WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds including a WDR5 ligand, a degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of WDR5-mediated diseases.

US Patent:

20220288207, Sep 15, 2022

Filed:

Jul 24, 2020

Appl. No.:

17/629707

Inventors:

- Boston MA, US
- New York NY, US
Husnu Umit KANISKAN - New York NY, US
He CHEN - New York NY, US
Jing LIU - Boston MA, US

Assignee:

Beth Israel Deaconess Medical Center, Inc. - Boston MA
Icahn School of Medicine at Mount Sinai - New York NY

International Classification:

A61K 41/00
A61K 47/55
A61K 47/54
A61P 35/00

Abstract:

By hijacking endogenous E3 ligase to degrade protein targets via the ubiquitin-proteasome system, PROTACs (PRoteolysis TArgeting Chimeras) provide a new strategy to inhibit protein targets that were previously regarded as undruggable. The compounds described herein comprise a photolabile group on PROTACs, enabling the degradation of protein targets in a spatiotemporally controlled manner By adding a photolabile caging group on ubiquitin recruiting moieties, light-inducible protein degradation was acheived. These opto-PROTACs display no activity in the dark, while restricted degradation can be induced at a specific time and rate by UVA-irradiation. Accordingly, these compounds provide light-controlled PROTACs and methods of using such compounds.

US Patent:

20230070613, Mar 9, 2023

Filed:

Jul 3, 2019

Appl. No.:

17/256516

Inventors:

- New York NY, US
Hanna Irie - New York NY, US
Jing Liu - New York NY, US
Yan Xiong - New York NY, US
Jessica Byerly - New York NY, US
Shannon Tomita - New York NY, US
Jianping Hu - New York NY, US

International Classification:

A61K 47/54
A61P 35/00
A61K 45/06

Abstract:

Disclosed herein are protein tyrosine kinase 6 (PTK6) degradation/disruption compounds including a PTK6 ligand, a N degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of FTK6-mediated diseases.